Allogene Therapeutics Selects Standard Fludarabine and Cyclophosphamide Regimen for Lymphodepletion in ALPHA3 Study

Strategic Insights -

Allogene Therapeutics, Inc. has announced the selection of standard fludarabine and cyclophosphamide (FC) as the lymphodepletion regimen for its ALPHA3 study evaluating cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma (LBCL). This decision was made following a Grade 5 adverse event in the FC plus ALLO-647 arm that has been attributed to the use of ALLO-647, a anti-CD52 monoclonal antibody.

The ALPHA3 study will proceed as a randomized study with two arms, comparing cema-cel after standard FC lymphodepletion to observation, the current standard of care. The amended trial will include over 50 clinical sites across the United States and Canada, including community cancer centers and major academic institutions. The next milestone for the trial will be the futility analysis comparing minimal residual disease (MRD) conversion, which is expected to occur in the first half of 2026.

The decision to advance AlloCAR T product candidates using the proprietary Dagger(r) Platform Technology was made to minimize or potentially eliminate the need for standard lymphodepletion. This platform is designed to reduce the risk of severe viral infections and other adverse events associated with ALLO-647.

Certain statements contained in this Current Report on Form 8-K are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include, without limitation, statements regarding intentions, beliefs, projections, outlook, analysis or current expectations concerning, among other things: the Company's ongoing ALPHA3 trial; the potential cause of the Grade 5 adverse event; the potential benefits of cema-cel, including as a potential first-line consolidation treatment for LBCL; the Company's plans to advance its AlloCAR T product candidates using the proprietary Dagger(r) Platform Technology; and the expectation that the futility analysis comparing MRD conversion will occur in the first half of 2026.

Key Takeaways:

  • Allogene Therapeutics, Inc. has filed a FORM 8-K with the U.S. Securities and Exchange Commission announcing the selection of standard fludarabine and cyclophosphamide (FC) as the lymphodepletion regimen for its ALPHA3 study evaluating cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma (LBCL).
  • The decision was made following a Grade 5 adverse event in the FC plus ALLO-647 arm that has been attributed to the use of ALLO-647.
  • The ALPHA3 study will proceed as a randomized study with two arms, comparing cema-cel after standard FC lymphodepletion to observation, the current standard of care.
  • The amended trial will include over 50 clinical sites across the United States and Canada, including community cancer centers and major academic institutions.
  • The next milestone for the trial will be the futility analysis comparing minimal residual disease (MRD) conversion, which is expected to occur in the first half of 2026.
  • Allogene Therapeutics, Inc. plans to advance its AlloCAR T product candidates using the proprietary Dagger(r) Platform Technology.
  • The Dagger(r) Platform Technology is designed to minimize or potentially eliminate the need for standard lymphodepletion and reduce the risk of severe viral infections and other adverse events associated with ALLO-647.
  • Certain statements contained in this Current Report on Form 8-K are forward-looking statements that involve a number of risks and uncertainties.

Statistics:

  • Over 50 clinical sites are activated across the United States and Canada for the ALPHA3 study.
  • The trial will proceed as a randomized study with two arms, comparing cema-cel after standard FC lymphodepletion to observation.
  • The next milestone for the trial will be the futility analysis comparing minimal residual disease (MRD) conversion, which is expected to occur in the first half of 2026.
  • The forward-looking statements in this report involve a number of risks and uncertainties.

Sources:

  • UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT (August 1, 2025)
  • Allogene Therapeutics, Inc. (August 1, 2025)
  • Securities and Exchange Commission. (1995). Private Securities Litigation Reform Act of 1995. Public Law 104-67.